EMA Withdrawn: Arzerra (ofatumumab) — Novartis Europharm Ltd

View source ↗

Summary

EMA has withdrawn Arzerra (ofatumumab) from the market in Europe.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia

Drugs mentioned

• Arzerra (ofatumumab)

Snippet

Status: Withdrawn. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell. MAH: Novartis Europharm Ltd. Decision date: 02/10/2017